<DOC>
	<DOCNO>NCT01120171</DOCNO>
	<brief_summary>This study evaluate efficacy , safety effect quality life liposomal-encapsulated doxorubicin combination cyclophosphamide first second line treatment old patient ( ≥ 70 year old ) metastatic breast cancer . The efficacy combination correlate functional status patient accord comprehensive geriatric assessment</brief_summary>
	<brief_title>Myocet Plus Endoxan Older Patients With Breast Cancer</brief_title>
	<detailed_description>Elderly individual make large part breast cancer population . When treated chemotherapy metastatic disease derive similar benefit young counterpart . Anthracyclines associate cumulative dose-dependent cardiomyopathy increase rate patient age 70 . Liposomal-encapsulated doxorubicin improve therapeutic index doxorubicin reduce significantly cardiotoxicity grade 4 neutropenia provide comparable antitumor efficacy , use combination cyclophosphamide first-line therapy metastatic breast cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically cytologically confirm metastatic breast adenocarcinoma No one prior therapy regimen ( hormonal therapy ) metastatic breast cancer acceptable . Measurable disease define presence least one measurable lesion ( except bone metastasis , ascites pleural effusion ) Performance status ( WHO ) 02 Adequate liver ( serum bilirubin &lt; 1.5 time upper normal limit , AST ALT &lt; 2.5 time upper normal limit absence demonstrable liver metastasis , &lt; 5 time upper normal limit presence liver metastasis ) Adequate renal function ( serum creatinine &lt; 1.5 time upper normal limit ) Adequate cardiac function ( LVEF within normal limit ) Adequate bone marrow function ( neutrophils ≥ 1.5x 109 /L , platelet ≥ 100x 109 /L ) No radiation measurable disease ( except brain metastasis ) No progressive brain metastasis accord clinical radiological criterion No brain metastases without prior radiation therapy Written inform consent Active infection History significant cardiac disease ( unstable angina , congestive heart failure , myocardial infarction within previous 6 month , ventricular arrhythmia ) Prior treatment anthracyclinecontaining regimen ( adjuvant therapy ) previous 12 month period Other invasive malignancy except nonmelanoma skin cancer Psychiatric illness social situation would preclude study compliance Pregnant lactating woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Elderly</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Cardiotoxicity</keyword>
</DOC>